FDA-Approved Drop XDEMVY Offers Targeted Relief for Demodex Blepharitis Patients, Modern Vision Solutions Reports

OMAHA, NE – January 22, 2026 – PRESSADVANTAGE –

Modern Vision Solutions has announced the publication of a new article, “Demodex Blepharitis Treatment in Omaha,” highlighting a significant shift in how optometrists approach the treatment of chronic eyelid inflammation caused by microscopic Demodex mites. The article details the latest clinical guidance and treatment protocols available at Modern Vision Solutions, including the use of XDEMVY, the first and only FDA-approved medication specifically developed to kill Demodex mites and treat Demodex blepharitis. This marks a meaningful update in standard care for patients who have long struggled with undiagnosed symptoms such as itching, redness, eyelash loss, and recurrent styes.

Demodex blepharitis has historically been difficult to diagnose due to the subtle appearance of collarettes—cylindrical debris at the base of the eyelashes that indicate mite infestation. According to recent studies cited in the article, more than two-thirds of blepharitis cases in the United States are associated with Demodex mites, and over half of patients seen in eye care clinics exhibit collarettes. These findings suggest that Demodex involvement in eyelid disease has been significantly under-recognized. The article underscores the importance of slit-lamp examinations focused specifically on identifying these signs in patients with chronic or treatment-resistant eyelid inflammation.

Traditional approaches to treating Demodex blepharitis—such as warm compresses, lid hygiene routines, microblepharoexfoliation, and the use of tea tree oil–based products—have typically offered only short-term relief. In cases of significant inflammation or comorbidities such as rosacea or keratitis, adjunct therapies like oral or topical ivermectin or metronidazole have been used. However, recurrence has remained a persistent challenge. The introduction of XDEMVY represents a shift in strategy, offering a targeted solution to eliminate the root cause rather than manage symptoms temporarily.

XDEMVY contains lotilaner 0.25%, a molecule that selectively targets neural channels in Demodex mites while sparing human receptors. This precision mechanism helps reduce mite counts, clear collarettes, and relieve associated inflammation without relying on the more abrasive or inconsistent therapies previously used. Clinical trials have demonstrated that after six weeks of treatment with XDEMVY, a majority of patients experienced substantial improvement, including near-complete clearing of collarettes and reduced eyelid redness. The treatment was well tolerated, with only mild, short-lived stinging reported in a small subset of participants. These data points form the foundation for its integration into current Demodex blepharitis treatment protocols.

Modern Vision Solutions emphasizes that XDEMVY is now frequently recommended as a first-line therapy for confirmed cases of Demodex blepharitis. The treatment regimen is straightforward: one drop in each eye, twice daily, for six weeks. Contact lens wearers are advised to remove lenses prior to instillation and wait at least 15 minutes before reinsertion. Patients using additional ophthalmic medications should space each application by at least five minutes to ensure proper absorption and efficacy. For individuals with coexisting ocular conditions such as rosacea or meibomian gland dysfunction, personalized treatment plans can be developed to promote comprehensive healing.

The article also addresses how XDEMVY fits into a broader patient care plan. While daily lid hygiene may still be recommended for general eyelid maintenance, the need for harsh cleansers or long-term hygiene routines is significantly reduced when the underlying mite infestation is eliminated. This has important implications for patient quality of life, particularly for individuals who have relied on repeated treatments with limited success. The article notes that identifying the actual cause of symptoms, rather than assuming allergy or dry eye as the default diagnosis, is key to delivering effective and lasting care.

With growing awareness of the prevalence of Demodex blepharitis, the need for optometrists to evaluate patients using updated diagnostic standards is becoming increasingly clear. The publication of “Demodex Blepharitis Treatment in Omaha” reflects a broader commitment by Modern Vision Solutions to align its clinical protocols with the most current research and treatment options available in the field of optometry. By offering patients access to advanced diagnostic tools and the latest FDA-approved therapies, the practice aims to reduce the time to diagnosis and improve long-term outcomes for those affected by this common but under-recognized condition.

To read the full article or to learn more about the optometric services offered at Modern Vision Solutions, visit Modern Vision Solutions. For press inquiries or to request interviews regarding this report, please contact the team directly through the website’s contact page.

###

For more information about Modern Vision Solutions – Omaha, contact the company here:

Modern Vision Solutions – Omaha
Jordan Maddex-Kopp
(833) 586-2020
marketing@alignedmanagementservices.com
10345 Pacific St.
Omaha, NE 68114